T1	Participants 63 90	chronic alcoholic patients.
T2	Participants 194 322	32 randomly selected hospitalized male alcoholic patients with clinical, biochemical and histological evidence of hepatic damage
T3	Participants 1020 1049	patients of the treated group
T4	Participants 1071 1084	placebo group
T5	Participants 1222 1264	patients with alcoholic liver disease (ALD
